REGAINS WORLDWIDE RIGHTS OF HEXVIX
Photocure has reached an agreement with Ipsen to regain rights for the sales
and marketing of Hexvix[®] in Europe
· The transaction is expected to be EBITDA accretive from FY 2021
· Ipsen achieved Hexvix 2019 sales of EUR 18.7 million and Photocure sees
significant growth opportunities in Europe
Oslo, Norway, 27 April 2020: Photocure ASA (Photocure, PHO: OSE) has reached an
agreement with Ipsen Pharma SAS (Ipsen) on key terms for the return of Hexvix
sales, marketing and distribution rights in Europe and other markets currently
controlled by Ipsen. With taking direct control over Photocure's own
Hexvix/Cysview product in key regions, the company supports the ambition of
becoming a global leader in bladder cancer with a solid basis for expansion and
further growth opportunities. Following a final agreement, Photocure will
commence the Hexvix commercialization in Europe from the fourth quarter of 2020
and expects the potential Ipsen agreement to be EBITDA accretive from full-year
2021 and beyond.
"We have agreed terms with Ipsen for a transformative agreement in our strategy
of building a strong and profitable global business within the diagnosis and
treatment of bladder cancer. We have built a successful commercial organization
for Hexvix/Cysview in the U.S. and the Nordics, with a solid underlying growth
potential post the COVID-19 situation. Photocure aims to apply lessons learned
in Nordic and U.S. and sees significant growth opportunities in Europe and other
markets currently not served by Ipsen," says Dan Schneider, President and CEO,
and continues:
"The agreement will provide a platform for growth when returning to normal
market conditions and we see the terms as financially highly attractive. The
agreement is expected to be EBITDA accretive from full-year 2021 and beyond.
Photocure sees major opportunities in Europe for accelerated growth and
expansion going forward."
Photocure entered into a global commercialization agreement with Ipsen in 2011
for the sales, marketing and distribution of Hexvix outside the Nordic region
and the U.S. Ipsen has served as strategic partner and has built a solid
position for the brand in select key European markets. Photocure today announces
that the company has agreed terms for an agreement with Ipsen to regain the
global commercialization of Hexvix following the company's pure-play bladder
cancer focus, solid track-record from other markets and a commercial opportunity
provided by Ipsen's strategic priorities going forward.
"The alliance with Ipsen was entered into at a time where Photocure was set on
developing multiple medical solutions based on our photodynamic technology
platform. Photocure has since re-positioned the company and decided to focus
exclusively on bladder cancer. To retrieve the rights for developing Hexvix in
major markets brings flexibility and expansion at a perfect point in time. There
is a considerable and growing interest in the bladder cancer market, as the
disease remains the most expensive cancer to treat, and we see significant
opportunities ahead," Schneider comments.
The parties have entered into a term sheet setting out the key terms and
conditions for an agreement. Pursuant to the term sheet, Photocure will, by the
fourth quarter of 2020, pay Ipsen EUR 15 million and at the same date regain all
Hexvix marketing rights from Ipsen subject to satisfaction of closing
conditions. Ipsen will book sales up until these dates. Ipsen will in addition
receive earn-out payments in the range of 10-15% of sales (years 1-7 post
-termination) and 7.5% of sales (years 8-10) in the current Ipsen markets.
Current market conditions are affected by the COVID-19 virus outbreak. The
development in both Photocure's operations as well as relevant financial markets
in general may have a significant impact on the feasibility of concluding any
agreement. See OSE notification of 7 April 2020 for an in-depth analysis of risk
and effects of the COVID-19 situation.
The final agreement with Ipsen will be subject to customary terms and
conditions, as well as adequate financing to complete settlement. Photocure had
a cash position at the end of 2019 of NOK 125 million and may in addition
satisfy the financing condition by way of equity or debt, or a combination
thereof. Further, Photocure has had advanced discussions and received offers
from debt providers, and agreements on financing may be entered into to ensure
completion of settlement.
Photocure expects to outline the following key financial targets for the
acquired rights, pending a final agreement:
· 2019 royalty received by Photocure was NOK 61 million excluding IFRS
adjustments. Following the potential transfer of the rights for the Ipsen
territories to Photocure, the revenue recognized by Photocure is expected to
increase around 3x to 2021 compared to 2019, driven by Photocure being granted
the in-market sale in the territories and growth in market penetration. Beyond
FY 2021, Photocure is targeting 20-30% annual revenue growth in current Ipsen
territories
· NOK 30 million in integration and ramp-up costs in 2020
· Around NOK 90 million in increased SG&A costs in Europe from FY 2021 and
beyond, with NOK 30-35 million increase for 2020
Outlines updated potential group 2023 ambitions
Photocure delivers transformative solutions which improve the lives of bladder
cancer patients. Based on experience and the performance of the breakthrough
bladder cancer product Hexvix/Cysview, Photocure has embarked on a stepwise
approach to continued growth. Photocure sees significant long-term value
creation potential in the global bladder cancer market and has developed a
defined growth strategy:
· Accelerating - Drive the breadth and depth of Hexvix/Cysview usage in key
accounts
· Expanding - Generate sales in new geographies and product enhancements
· Acquiring - Products used in the management of bladder cancer patients
· Transforming - Partner and in-license assets to strengthen the bladder
cancer portfolio
The primary growth geographies for Photocure are the U.S. and European markets
with large untapped market opportunities. The company will regain the sales and
marketing rights from Ipsen in the fourth quarter of 2020 and sees significant
growth opportunities in Europe. The agreement is expected to be EBITDA accretive
from full-year 2021 and beyond.
Based on the outlook and strategic opportunities, Photocure aims to increases
its group revenue ambitions for 2023 in the range of NOK 1 billion with EBITDA
margins of approximately 40%, following the completion of the potential
transaction.
EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
first quarter 2020 financial report on pages 20-21.
https://newsweb.oslobors.no/message/503877
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Anders9ls1
27.04.2020 kl 16:57
3873
Photocure ASA - Contemplated Private Placement
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Photocure ASA - Contemplated Private Placement Oslo, Norway, 27 April 2020: Photocure ASA ("Photocure" or the "Company") has retained ABG Sundal Collier ASA and DNB Markets, a part of DNB Bank ASA as Joint Bookrunners (collectively referred to as the "Managers") to advise on and effect a contemplated private placement directed towards Norwegian and international investors, subject to and in compliance with applicable exemptions from relevant prospectus or registration requirements (the "Private Placement"). The Company is contemplating to issue up to 2,179,638 new shares in the Company (the "Offer Shares"). The Company intends to use the net proceeds from the Private Placement for to finance the acquisition of the Hexvix sales, marketing and distribution rights from Ipsen Pharma SAS and general corporate purposes. Please see a separate stock exchange announcement released by the Company today, 27 April 2020, regarding the acquisition. The subscription price and the number of Offer Shares to be issued in the Private Placement will be determined by the board of directors of the Company (the "Board") following an accelerated bookbuilding process. The application period for the Private Placement will commence on 27 April 2020 at 16:30 hours CEST and is expected to close on 28 April 2020 at 08:00 hours CEST. The Company, after consultation with the Managers, reserves the right to at any time and in its sole discretion resolve to close or to extend the application period or to cancel the Private Placement in its entirety without further notice. If the Application Period is shortened or extended, any other dates referred to herein may be amended accordingly. The minimum subscription and allocation amount in the Private Placement will be the NOK equivalent of EUR 100,000, provided that the Company may, at its sole discretion, allocate an amount below EUR 100,000 to the extent applicable exemptions from the prospectus requirement pursuant to applicable regulations, including the Norwegian Securities Trading Act and ancillary regulations, are available. The allocation will be made at the sole discretion of the Board after input from the Managers. Allocation will be based on criteria such as (but not limited to), existing ownership in the Company, timeliness of the application, price leadership, relative order size, sector knowledge, investment history, perceived investor quality and investment horizon. The Board may, at its sole discretion, reject and/or reduce any applications. There is no guarantee that any applicant will be allocated Offer Shares. The Offer Shares will be issued based on a Board authorization granted by the Company's annual general meeting held on 9 May 2019. The Managers are expected to pre-fund the subscription price for the Offer Shares to facilitate a swift registration of the share capital in the Norwegian Register of Business Enterprises (“NRBE”). The Offer Shares will be tradeable from the registration of the share capital increase in the NRBE. Delivery of the Offer Shares will be on a delivery versus payment basis to the investors. The Company will announce the results of the Private Placement in a stock exchange announcement expected to be published before opening of markets tomorrow, 28 April 2020. Completion of the Private Placement is subject to final approval by the Board. The Board of Directors has considered the Private Placement in light of the equal treatment obligations under the Norwegian Securities Trading Act and Oslo Børs' Circular no. 2/2014, and is of the opinion that the proposed Private Placement is in compliance with these requirements. The Board has considered alternative structures for the raising of new equity. Following careful considerations, the Board is of the view that it will be in the common interest of the Company and its shareholders to raise equity through a private placement setting aside the pre-emptive rights of the shareholders. By structuring the transaction as a private placement, the Company expects to be in a position to complete the share issue in today's market conditions in an efficient manner. It also gives the Company the possibility of raising equity with a lower discount to the current trading price and with significantly lower execution risks compared to a rights issue. In addition, the Private Placement has been subject to a pre-sounding and is subject to a publicly announced bookbuilding process. By this, a market based subscription price will be achieved. Advokatfirmaet Selmer AS is acting as legal adviser to Photocure ASA.
16:54 PHO: Photocure ASA - Contemplated Private Placement https://newsweb.oslobors.no/message/503878
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Photocure ASA - Contemplated Private Placement Oslo, Norway, 27 April 2020: Photocure ASA ("Photocure" or the "Company") has retained ABG Sundal Collier ASA and DNB Markets, a part of DNB Bank ASA as Joint Bookrunners (collectively referred to as the "Managers") to advise on and effect a contemplated private placement directed towards Norwegian and international investors, subject to and in compliance with applicable exemptions from relevant prospectus or registration requirements (the "Private Placement"). The Company is contemplating to issue up to 2,179,638 new shares in the Company (the "Offer Shares"). The Company intends to use the net proceeds from the Private Placement for to finance the acquisition of the Hexvix sales, marketing and distribution rights from Ipsen Pharma SAS and general corporate purposes. Please see a separate stock exchange announcement released by the Company today, 27 April 2020, regarding the acquisition. The subscription price and the number of Offer Shares to be issued in the Private Placement will be determined by the board of directors of the Company (the "Board") following an accelerated bookbuilding process. The application period for the Private Placement will commence on 27 April 2020 at 16:30 hours CEST and is expected to close on 28 April 2020 at 08:00 hours CEST. The Company, after consultation with the Managers, reserves the right to at any time and in its sole discretion resolve to close or to extend the application period or to cancel the Private Placement in its entirety without further notice. If the Application Period is shortened or extended, any other dates referred to herein may be amended accordingly. The minimum subscription and allocation amount in the Private Placement will be the NOK equivalent of EUR 100,000, provided that the Company may, at its sole discretion, allocate an amount below EUR 100,000 to the extent applicable exemptions from the prospectus requirement pursuant to applicable regulations, including the Norwegian Securities Trading Act and ancillary regulations, are available. The allocation will be made at the sole discretion of the Board after input from the Managers. Allocation will be based on criteria such as (but not limited to), existing ownership in the Company, timeliness of the application, price leadership, relative order size, sector knowledge, investment history, perceived investor quality and investment horizon. The Board may, at its sole discretion, reject and/or reduce any applications. There is no guarantee that any applicant will be allocated Offer Shares. The Offer Shares will be issued based on a Board authorization granted by the Company's annual general meeting held on 9 May 2019. The Managers are expected to pre-fund the subscription price for the Offer Shares to facilitate a swift registration of the share capital in the Norwegian Register of Business Enterprises (“NRBE”). The Offer Shares will be tradeable from the registration of the share capital increase in the NRBE. Delivery of the Offer Shares will be on a delivery versus payment basis to the investors. The Company will announce the results of the Private Placement in a stock exchange announcement expected to be published before opening of markets tomorrow, 28 April 2020. Completion of the Private Placement is subject to final approval by the Board. The Board of Directors has considered the Private Placement in light of the equal treatment obligations under the Norwegian Securities Trading Act and Oslo Børs' Circular no. 2/2014, and is of the opinion that the proposed Private Placement is in compliance with these requirements. The Board has considered alternative structures for the raising of new equity. Following careful considerations, the Board is of the view that it will be in the common interest of the Company and its shareholders to raise equity through a private placement setting aside the pre-emptive rights of the shareholders. By structuring the transaction as a private placement, the Company expects to be in a position to complete the share issue in today's market conditions in an efficient manner. It also gives the Company the possibility of raising equity with a lower discount to the current trading price and with significantly lower execution risks compared to a rights issue. In addition, the Private Placement has been subject to a pre-sounding and is subject to a publicly announced bookbuilding process. By this, a market based subscription price will be achieved. Advokatfirmaet Selmer AS is acting as legal adviser to Photocure ASA.
16:54 PHO: Photocure ASA - Contemplated Private Placement https://newsweb.oslobors.no/message/503878
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Andobackman
27.04.2020 kl 17:07
3789
Det er en god nyhet det!
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
FunHouseComp
27.04.2020 kl 17:17
3676
Spørsmålet er hva pafo mener om dette :)
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
SomSa
27.04.2020 kl 17:22
3616
Pho skal betale ca. 158 mil kroner til Ipsen + PHO skal betale en vis prosent av salget
PHO må selv bygge salgsorganisasjon i Europa og når vi vet at salget går treg i USA vet vi allerede at hva kommer til å skje i Europa.
Skal de ha en salgssjef for Europa med million lønn, bonus og diverse goder?
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
JosefK
27.04.2020 kl 17:22
3601
Jaja, dette har jeg sagt noen år. Det ble en høy pris for å parkere Ipsen men det var nok like greit.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
risksøker
27.04.2020 kl 17:29
3533
DS sier målet er 1 milliard i omsetning i 2023 og EBITA margin på 40%. Dette blir bra.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Based on the outlook and strategic opportunities, Photocure aims to increases its group revenue ambitions for 2023 in the range of NOK 1 billion with EBITDA margins of approximately 40%, following the completion of the potential transaction.
Det er om 2 år!
Det er om 2 år!
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
SomSa
27.04.2020 kl 17:39
3434
PHO med en hær av selgere i USA klarer å øke salget i USA med russiske prosenter. Vi kan forvente kraftig kostnadsøkning i 2Q, og 3Q:
NOK 30 million in integration and ramp-up costs in 2020
Around NOK 90 million in increased SG&A costs in Europe from FY 2021 and
beyond, with NOK 30-35 million increase for 2020
Totalt: 150-155 mil
I følge børsmeldingen 7 April 2020
The company had a cash position of NOK 123 million at the end of March 2020 and carries no interest-bearing debt
158 mil (Ispen regning) + 155 mil (Europa kostnader) = 313 mil
Har jeg regnet riktig? De tjener heller ikke penger, enten må de gjennomføre en ny emisjon eller låne penger.
De skal trykke 2,179,638 aksjer, med kurs 69 kan de hente ca. 150 mil. Tilretteleggere skal få 3%-7% av emisjonen og PHO vil sitte med 145,5 - 139,5 mil
Etter emisjonen har de: 145,5 eller 139,5 mil + 123 mil = 262,5 mil -268,5 mil
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
SomSa
27.04.2020 kl 17:46
3352
Glem guidingen for 2023, det er bare full fantasi og tull. I 2017 kom de med guiding på usd 20 mil -usd 25 mil for 2017 for Surveillance markedet. Dette skulle økes etter at de skulle få refusjonsordning for TURBT markedet. TURBT markedet er 3,5-4 ganger større enn Surveillance markedet. I 2019 økte ikke guidingen og behold samme guidingen selv om de fikk refusjonen i 2018. I 2020 skjønte vi at de heller ikke oppnår denne guidingen. Daniel i desperasjon kom med en 2023 guiding...........
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Fare for at dette er bare den første av flere. Blir vel en ny emisjon for hvert land i europa som de skal dekke. Tatt i betraktning at dagens emi dekker maksimal tilbakekjøpet av Ibsen rettigheter....
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Og det gjorde Dan the man kun ca seks måneder etter at han selv nesten idiotforklarte guidinger som ligger flere år fram i tiden. Så gjør han det selv........
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
SomSa
27.04.2020 kl 17:49
3292
Daniel burde ha fått sparken, fyren med en hær av selgere har ikke oppnådd noe i USA og han skal styre også Europa nå.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Hvorfor det? Han klarer da sikkert å oppnå det samme i Europa. Menigheten er ja stort sett tilfreds med fyren. Bortsett fra Hansen da, som muligens viste hva som kom gjennom sine to styremedlemmer som han visstnok fikk installert.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
clanz
27.04.2020 kl 18:00
3167
Overraskende at de henter penger nå.... midt under Covid-19.
De kan jo ta opp mye gjeld med så god historikk på inntektene som de har i Europa.
De kan jo ta opp mye gjeld med så god historikk på inntektene som de har i Europa.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Ja det ser jo bra ut, men eg undrer jo litt om Ibsen har en omsettning på 18,7 mil Euro i året. Hvorfor da selge for 15 mil Euro.
Det låter ikke logiskt,men det vi ikke vet er vad EBITDA er for Ipsen. Men att PHO skall få ha ett salg på 1 mrd, før seg selv
uten patent, er tvivelaktigt. Men att Schneider har storhetsvansinne har eg påpekt mange ganger før, man sitter igjen med
en kjennsle av att det kommer gå evigheter innen de redoviser noen større vinst. Men en del prioriterer jo vekst føre vinst.
Det kom overraskende på og blir noe att fundere på.
Det låter ikke logiskt,men det vi ikke vet er vad EBITDA er for Ipsen. Men att PHO skall få ha ett salg på 1 mrd, før seg selv
uten patent, er tvivelaktigt. Men att Schneider har storhetsvansinne har eg påpekt mange ganger før, man sitter igjen med
en kjennsle av att det kommer gå evigheter innen de redoviser noen større vinst. Men en del prioriterer jo vekst føre vinst.
Det kom overraskende på og blir noe att fundere på.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Oregon
27.04.2020 kl 18:06
3095
Er nok litt i tvil om dette er riktig tidspunkt. Ipsen inntektene har tross alt kommet tikkende inn hvert kvartal et sted i størrelsesorden mellom 15 og 18 mill. kr. uten større kostnader for PHO.
Nå skal de altså bruke alt av egenkapital og litt til for å kjøpe tilbake rettighetene Ipsen besitter pluss at de selv må bygge opp en egen formodentlig større salgsorganisasjon med alt det innebærer av også kostnader i flere av landene ( Tyskland, Frankrike mm.).
Jeg er litt i tvil om tidspunktet nå som jeg skriver over fordi med USA som eksempel så er det svært kostnadskrevende å bygge opp og å ha en egen salgsorganisasjon og isolert sett så går USA satsingen og salget samlet sett i minus og jeg hadde helst sett at de hadde fått bekreftet betydelige positive resultater der før de satte i gang igjen selv i Europa.
Går alt litt i tillegg tregt fremover ser jeg ikke bort i fra at selveste PHO også må hente inn noe penger eller starte opplåning som vel også nevnes i pressemeldingen.
Så i utgangspunktet er jeg ikke overbevist om at dette var riktig å gjøre nå og jeg tror kanskje markedet vil oppfatte dette litt negativt( usikkerhet på kort sikt i disse tider).
Samtidig bør sies at når PHO nå samler denne delen igjen under egen paraply så kan jo det også være et krav eller et signal fra beilere ( Asia?) om at de ønsker kun en part å forholde seg til ved et oppkjøp.
Nå skal de altså bruke alt av egenkapital og litt til for å kjøpe tilbake rettighetene Ipsen besitter pluss at de selv må bygge opp en egen formodentlig større salgsorganisasjon med alt det innebærer av også kostnader i flere av landene ( Tyskland, Frankrike mm.).
Jeg er litt i tvil om tidspunktet nå som jeg skriver over fordi med USA som eksempel så er det svært kostnadskrevende å bygge opp og å ha en egen salgsorganisasjon og isolert sett så går USA satsingen og salget samlet sett i minus og jeg hadde helst sett at de hadde fått bekreftet betydelige positive resultater der før de satte i gang igjen selv i Europa.
Går alt litt i tillegg tregt fremover ser jeg ikke bort i fra at selveste PHO også må hente inn noe penger eller starte opplåning som vel også nevnes i pressemeldingen.
Så i utgangspunktet er jeg ikke overbevist om at dette var riktig å gjøre nå og jeg tror kanskje markedet vil oppfatte dette litt negativt( usikkerhet på kort sikt i disse tider).
Samtidig bør sies at når PHO nå samler denne delen igjen under egen paraply så kan jo det også være et krav eller et signal fra beilere ( Asia?) om at de ønsker kun en part å forholde seg til ved et oppkjøp.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
SomSa
27.04.2020 kl 18:18
2994
Skal de ikke presenteres 1Q 2020 5. mai? Kanskje er resultatet ikke god nok og de har hastverk å hente penger. I dette tilfelle kan være et riktig tidspunkt å hente penger. men de trenger mer enn 155 mill etter min utregning. Corona problemene kan være hele 2020........
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Kan du ikke være snill å vise oss din utregning, slik at vi vet hva som de gjør at du uttaler deg som du gjør.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
7.mai er q1.
Du har jo allerede antydet resultatet SomSa, har du glemt det?
Signaler som kommer er at emi ble fulltegnet på under en time.
Du har jo allerede antydet resultatet SomSa, har du glemt det?
Signaler som kommer er at emi ble fulltegnet på under en time.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Oregon
27.04.2020 kl 18:27
2905
Jeg fikk ikke med meg i første innlegg ( trodde første innlegg var limt inn to ganger) at de faktisk skal ha en emisjon nå også gjennom en Book Building Process. Blir spennende å se hva kursen på disse aksjene blir. Skal jeg tippe så blir det kanskje et sted rundt 55?
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Ryktes 65.
Men jeg kan ikke gå 100% god for det. Jeg har ikke tegnet meg.
De som er medlemmer i fb gruppen vil kunne se det der.
Men jeg kan ikke gå 100% god for det. Jeg har ikke tegnet meg.
De som er medlemmer i fb gruppen vil kunne se det der.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
mofi1
27.04.2020 kl 18:36
2843
Det må vel være bra, de øker jo antall aksjer med 10%?
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
SomSa
27.04.2020 kl 18:43
2789
Se på innlegg "kl 17:39" og med forbehold om feil.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Hva skal man si Pafo, DS er virkelig en mann som handler?
De fleste av oss har revet oss i håret over Ipsen sin slette innsats og hvordan man skal komme ut av det, DS har også flere ganger vært sterkt misfornøyd og setter handling bak sine ord!
De fleste av oss har revet oss i håret over Ipsen sin slette innsats og hvordan man skal komme ut av det, DS har også flere ganger vært sterkt misfornøyd og setter handling bak sine ord!
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
focuss
27.04.2020 kl 19:07
2641
Markedet er ikke alltid rasjonelt. Det er derfor noen av oss hele tiden blir rikere. Trist men sant.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
bj111
27.04.2020 kl 20:46
2382
Spår en nedgang ved emisjon så treffer man vel 90% av tilfellene ved Oslo Børs. Finnes vel ikke noe som er mer kurshemmende i Norge enn en emisjon. Alle aksjonærers skrekk i Norge.
Hvorvidt det er bra de tar salget selv skal jeg ikke uttale meg om men grunnen må jo være at de syntes salget i Europa er elendig.
Hvorvidt det er bra de tar salget selv skal jeg ikke uttale meg om men grunnen må jo være at de syntes salget i Europa er elendig.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare
Anders9ls1
27.04.2020 kl 22:22
2154
Photocure ASA - Private placement successfully placed
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Oslo, Norway, 27 April 2020: Reference is made to the stock exchange notice earlier today where Photocure ASA ("Photocure" or the "Company") announced the launch of a private placement of new shares ("Offer Shares") in the Company (the "Private Placement"). The Company is pleased to announce that it has allocated 2,179,638 shares at a subscription price of NOK 65.50 per share, raising gross proceeds of approximately NOK 143 million. The subscription price was determined through an accelerated bookbuilding process after close of trading on 27 April 2020. The Private Placement attracted very strong interest from existing shareholders, as well as from new high quality institutional investors. The Private Placement was multiple times oversubscribed. The Company intends to use the net proceeds from the Private Placement to partially finance the acquisition of the Hexvix sales, marketing and distribution rights from Ipsen Pharma SAS. The share capital increase of the Private Placement was resolved by the Board of Directors of the Company (the "Board") on 27 April 2020 pursuant to an authorization granted by the Company's general meeting held 9 May 2019. Notification of allotment of the new shares in the Private Placement and payment instructions will be sent to the applicants through a notification from the Managers on 28 April 2020. The Offer Shares will be pre-funded by the Managers to facilitate a swift registration of the share capital increase in the Norwegian Register of Business Enterprises (the "NRBE") and delivery of the Offer Shares on a delivery versus payment basis to the subscribers on or about 30 April 2020. The first day of trading is expected to be on or about 29 April 2020, but not prior to the share capital being registered in the NRBE, or prior to announcement by the Company. Following registration of the new share capital pertaining to the Private Placement, the Company will have a share capital of NOK 11,988,012.50 divided into 23,976,025 shares, each with a par value of NOK 0.50. ABG Sundal Collier ASA and DNB Markets, a part of DNB Bank ASA acted as Joint Bookrunners (collectively referred to as the "Managers") in the Private Placement. Advokatfirmaet Selmer AS is acting as legal adviser to Photocure ASA.
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Oslo, Norway, 27 April 2020: Reference is made to the stock exchange notice earlier today where Photocure ASA ("Photocure" or the "Company") announced the launch of a private placement of new shares ("Offer Shares") in the Company (the "Private Placement"). The Company is pleased to announce that it has allocated 2,179,638 shares at a subscription price of NOK 65.50 per share, raising gross proceeds of approximately NOK 143 million. The subscription price was determined through an accelerated bookbuilding process after close of trading on 27 April 2020. The Private Placement attracted very strong interest from existing shareholders, as well as from new high quality institutional investors. The Private Placement was multiple times oversubscribed. The Company intends to use the net proceeds from the Private Placement to partially finance the acquisition of the Hexvix sales, marketing and distribution rights from Ipsen Pharma SAS. The share capital increase of the Private Placement was resolved by the Board of Directors of the Company (the "Board") on 27 April 2020 pursuant to an authorization granted by the Company's general meeting held 9 May 2019. Notification of allotment of the new shares in the Private Placement and payment instructions will be sent to the applicants through a notification from the Managers on 28 April 2020. The Offer Shares will be pre-funded by the Managers to facilitate a swift registration of the share capital increase in the Norwegian Register of Business Enterprises (the "NRBE") and delivery of the Offer Shares on a delivery versus payment basis to the subscribers on or about 30 April 2020. The first day of trading is expected to be on or about 29 April 2020, but not prior to the share capital being registered in the NRBE, or prior to announcement by the Company. Following registration of the new share capital pertaining to the Private Placement, the Company will have a share capital of NOK 11,988,012.50 divided into 23,976,025 shares, each with a par value of NOK 0.50. ABG Sundal Collier ASA and DNB Markets, a part of DNB Bank ASA acted as Joint Bookrunners (collectively referred to as the "Managers") in the Private Placement. Advokatfirmaet Selmer AS is acting as legal adviser to Photocure ASA.
Redigert 20.01.2021 kl 22:23
Du må logge inn for å svare